Clinical trial
Naltrexone in Borderline Personality Disorder
NCT00124839 · Central Institute of Mental Health, Mannheim, Other · Terminated
Key facts
| NCT number | NCT00124839 |
|---|---|
| Title | Naltrexone in Borderline Personality Disorder |
| Official title | Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder |
| Lead sponsor | Central Institute of Mental Health, Mannheim, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Borderline Personality Disorder |
| Intervention type | Drug |
| Interventions | Naltrexone |
| Enrollment | 48 |
| Start date | Oct 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Jul 28, 2005 |
| Last update posted | Apr 15, 2008 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: